Kura Oncology (KURA) Free Cash Flow (2010 - 2026)

Kura Oncology (KURA) has 17 years of Free Cash Flow data on file, last reported at -$86.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 19.06% year-over-year to -$86.0 million in Q1 2026; TTM through Mar 2026 was -$84.5 million, a 176.4% decrease from a year earlier, with the FY2025 full-year figure at -$70.7 million, down 152.82% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$86.0 million, down from $115.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for KURA reached as high as $268.8 million in Q4 2024 and fell as low as -$86.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$15.2 million across 5 years, with a median of -$32.2 million in 2022.
• Across the five-year window, Free Cash Flow soared 883.01% in 2024 and plunged 91.51% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$26.5 million in 2022, then retreated by 29.32% to -$34.3 million in 2023, then surged by 883.01% to $268.8 million in 2024, then tumbled by 57.23% to $115.0 million in 2025, then tumbled by 174.8% to -$86.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$86.0 million in Q1 2026, $115.0 million in Q4 2025, and -$83.2 million in Q3 2025.